Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enavogliflozin Cardiorenal Outcomes in Type 2 Diabetes (ENVELOP)
NCT06642623Phase 4Recruiting
- Sponsor
- Yonsei University
- Start
- Jan 2024
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of enavogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Yonsei University. Started Jan 2024; status: recruiting.
02
Drugs
enavogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06642623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06642623.